Table 1. Clinical and biochemical characteristics of patients with biopsy-proven NAFLD stratified by early kidney dysfunction.

Variable	No EKD (n = 181)	EKD (n = 33)	P
Demographic parameters			
Age (year)	41.54 ± 13.32	48.21 ± 10.84	**0.007**
Male sex, n (%)	128 (70.71%)	14 (42.42%)	**0.002**
BMI (kg/m^2)	27.82 ± 5.29	30.51 ± 6.57	**0.010**
Hip circumference (cm)	101.29 ± 8.67	105.08 ± 14.05	**0.043**
Waist circumference (cm)	93.44 ± 11.47	99.06 ± 16.34	**0.019**
Ethnicity			0.071
White, n (%)	44 (24.31%)	13 (39.39%)	
Yellow, n (%)	137 (75.69%)	20 (60.61%)	
Clinical parameters			
Systolic BP (mmHg)	124.23 ± 18.14	134.13 ± 15.44	**0.005**
Diastolic BP (mmHg)	78.46 ± 10.81	83.33 ± 10.33	**0.022**
Hypertension, n (%)	36 (19.89%)	18 (54.55%)	**< 0.001**
Type 2 diabetes, n (%)	51 (28.18%)	21 (63.64%)	**< 0.001**
Laboratory parameters			
Hemoglobin A1c (%)	6.15 ± 1.51	6.42 ± 1.23	0.373
Fasting glucose (mmol/L)	5.67 ± 1.67	6.32 ± 3.18	0.127
Creatinine (µmol/L)	66.96 ± 14.03	73.66 ± 17.84	**0.017**
Uric acid (µmol/L)	372.46 ± 145.17	390.27 ± 101.70	0.496
Triglycerides (mmol/L）	2.30 ± 1.35	2.50 ± 1.51	0.447
Total cholesterol (mmol/L)	5.06 ± 1.34	5.58 ±1.36	0.076
LDL cholesterol (mmol/L)	3.04 ± 1.01	2.94 ± 1.19	0.616
HDL cholesterol (mmol/L)	1.06 ± 0.26	1.02 ± 0.22	0.540
Albumin (g/L)	46.52 ± 3.76	46.53 ± 3.46	0.989
eGFR (ml/min/1.73m^2)	109.53 ± 16.90	91.41 ± 19.20	**< 0.001**
eGFR category (%)			**< 0.001**
≥90 ml/min/1.73 m^2	160 (88.40%)	16 (48.48%)	
<90 ml/min/1.73 m^2	21 (11.60%)	17 (51.52%)	
HOMA-IR score	4.87 ± 6.32	7.81 ± 10.50	**0.034**
Liver fibrosis stage-biopsy			**0.006**
0	79 (43.65%)	4 (12.12%)	
1	64 (35.36%)	18 (54.55%)	
2	22 (12,15%)	5 (15.15%)	
3	16 (8.84%)	6 (18.18%)	

Sample size, n=214. BMI = body mass index, BP = blood pressure, EKD = early kidney dysfunction, eGFR = estimated glomerular filtration rate, HOMA-IR = homeostasis model assessment of insulin resistance, HDL = high-density lipoprotein, LDL = low-density lipoprotein